SeHCAT (tauroselcholic [75selenium] acid) is recommended by NICE for use in research to collect more information about its usefulness in the diagnosis and treatment of bile acid malabsorption.
SeHCAT, a radioactive drug, is the only test currently used to diagnose bile acid malabsorption, which can cause long-lasting debilitating diarrhoea. NICE assessed the use of SeHCAT to help the NHS decide whether to use this product for investigating diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome and in people with Crohn’s disease who have not had ileal resection. NICE concluded that that SeHCAT is potentially useful in this setting, but that there is not enough evidence to work out whether it is value for money.
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.